Análisis Argos
CLOV
CLOVSin veredicto3 señales de riesgo
Clover Health Investments, Corp. · Healthcare
US$ 5.26
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
26/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
Tiene más caja que deuda: balance fuerte.
Riesgos
!Venta significativa de insiders en el último trimestre.
!Altman Z'' en zona roja (-12.26)
!Piotroski F-Score débil (3/9)
VALOR1/6FUTURO6/6PASADO1/6SALUD0/6DIVIDENDO3/6
El Iris de calidad
VALOR1/6FUTURO6/6PASADO1/6SALUD0/6DIVIDENDO3/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial débil
SaludBalance frágil
DividendoRetorno al accionista moderado
Score Argos26de 100Sin veredicto
Ingresos40%
US$ 1.9 B
Margen operativo33%
-4.4%
Flujo de caja libre333%
US$ -0.1 B
Deuda neta
US$ -0.1 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 2.7B
P/E
EV/EBITDA
FCF yield-2.5%
ROIC-37.1%
Margen operativo-4.4%
Crecim. ingresos+40.3%/año
Piotroski F3/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

fool.com · 27 jun
A Clover Health Director Sold Over 67,000 Company Shares. Here's a Closer Look at the Transaction.
Director Carladenise Edwards sold 67,160 shares for a transaction value of approximately ~$230,000 on May 18, 2026, at a weighted average price of around $3.42 per share. This sale represented 19% of her direct holdings at the time, reducing direct ownership from 352,592 to 285,432 shares.
benzinga.com · 11 jun
Clover Health Stock Extends Gains After Court Forces CMS to Upgrade Medicare Star Rating
Clover Health Investments Corp. (NASDAQ:CLOV) shares are extending yesterday's 18.9% surge Thursday, after a court-ordered Medicare Star Rating upgrade jumped its PPO plan from 3.5 to 4.5 Stars.
fool.com · 5 jun
A Clover Health Insider Sold Over 220,000 Company Shares. What Does That Mean for Investors?
This healthcare technology company focused on Medicare Advantage plans saw a notable insider sale following a year of strong stock gains.
seekingalpha.com · 7 may
Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript
Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript
zacks.com · 7 may
Clover Health Q1 Earnings Meet Estimates, Sales Beat, Membership Rises
CLOV posts 62% revenue growth in Q1 as Medicare Advantage membership surges and AI-driven care initiatives boost profitability.
zacks.com · 6 may
Clover Health Investments, Corp. (CLOV) Meets Q1 Earnings Estimates
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.05 per share a year ago.
globenewswire.com · 6 may
Clover Health Reports First Quarter 2026 Results
Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross Profit Market-leading Medicare Advantage membership growth with underlying trends tracking in line with expectations Expect to meet or exceed full year 2026 outlook across all metrics, including achieving first full year GAAP Net Income profitability Financial Results: First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-year First quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-year First quarter 2026 Consolidated Gross Profit of $160 million, up 47% year-over-year, and Adjusted EBITDA of $40 million, up 56% year-over-year Full Year 2026 Guidance: Average Medicare Advantage membership of 154,000 - 158,000, representing 46% growth year-over-year at the midpoint Total revenues between $2.81 billion and $2.92 billion, representing 49% growth year-over-year at the midpoint Consolidated Gross Profit between $470 million and $510 million, representing 38% growth year-over-year at the midpoint Adjusted EBITDA profitability between $50 million and $70 million GAAP Net Income between $0 million and $20 million WILMINGTON, Del., May 06, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the first quarter 2026.
zacks.com · 30 abr
Butterfly Network, Inc. (BFLY) Reports Q1 Loss, Beats Revenue Estimates
Butterfly Network, Inc. (BFLY) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.06 per share a year ago.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.